Fig. 6: MVA-EbolaZ boost increased proportion of CD4+ and CD8 + T cells responding to Zaire epitopes by week 4. | npj Vaccines

Fig. 6: MVA-EbolaZ boost increased proportion of CD4+ and CD8 + T cells responding to Zaire epitopes by week 4.

From: Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trials

Fig. 6

Percentage of memory background-subtracted CD4 (a, b) and CD8 (c, d) T cells responding to ex vivo stimulation with production of any tested cytokine at baseline and four weeks post-MVA vaccination in US (a, c) and UG (b, d) participants. Box plots denote median with upper and lower quartiles of each group. Dotted line indicates background cytokine production in the absence of stimulation. For each group, titers were compared between baseline and week 4 using the Wilcoxon rank-sum test, and statistical significance is reported above each group for which p < 0.05.

Back to article page